secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001104659-24-046247
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics updates pipeline; CNTY-101 shows durable responses, no allo-rejection in Ph1
--------------------------------------------------------------------------------

- CNTY-101 (CD19 iNK) in Ph1 ELiPSE-1 shows favorable safety, 2 CRs including 6-month durable CR, no allo-rejection.
- Plan to initiate Ph1 CALiPSO-1 trial in SLE in H1 2024; initial data expected by YE 2024.
- Cash, cash equivalents, and investments of $261.8M at end of Q4 2023; runway into 2026.
- Platform includes Allo-Evasion edits enabling repeat dosing without lymphodepletion; advancing iNK and γδ iT cell programs.
- Additional ELiPSE-1 data expected mid-2024; pursuing additional autoimmune health authority filings in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924046247/0001104659-24-046247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924046247/tm2411557d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-046247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer